Manning-Geist BL, et al. - Researchers analyzed data on demographics, operative characteristics, and outcome from stage IIIC-IV epithelial ovarian cancer patients managed with neoadjuvant chemotherapy and interval debulking surgery (IDS) from January 2010 to July 2015 to investigate the impact of perioperative red blood cell transfusion (PRBCT) on infection, thrombosis, or survival rates in these subjects. They assessed the associations of PRBCT with morbidity and oncologic outcomes. PRBCT was received by 136 (50.4%) of 270 patients. PRBCT was more likely to be performed in patients with preoperative anemia and higher estimated blood loss, as well as in those with moderate and high complexity surgeries vs low complexity operations. Overall, similar rates were observed for intraabdominal infection, wound complication and venous thromboembolism/pulmonary embolism, regardless of PRBCT, among patients undergoing NACT-IDS. No impact of PRBCT on progression-free survival or overall survival was seen.